AI Drug Discovery Specialised for Cardiovascular Disease
AI driven collation and analysis of highly fragmented datasets to form the industry's most representative and holistic cardiovascular metabolic pathway maps
Data integrated into CardiaTec's proprietary Cardiosome* database, for targeted analysis and integrated pathway modelling
Leveraging AI for target identification and novel drug discovery to deliver the next generation of therapeutics for cardiovascular diseases
Transforming current one-size-fits-all approaches to personalised and effective medical intervention
Head of Artificial Intelligence at Milner Therapeutics Institute, Associate Faculty at Cambridge Centre for AI in Medicine, University of Cambridge.
BSc Biology, MSc Biotechnology & MPhil Bioscience Enterprise, University of Cambridge, with previous experience in life science project managment & Consulting.
BSc Bioengineering & MPhil Bioscience Enterprise, University of Cambridge, with previous experience in life science VC & Consulting.
Get in touch
Contact us for more information on our approach, collaborations and for joining us on a unique venture: